Lastly, as mTOR was overexpressed in DLBCL compared with control samples (Figure 3G), we investigated its expression in CD86+ cells in DLBCL samples (intra-T vs peri-T) and in DLBCL vs non-tumor control (lymph nodes) samples. This evidence concerns the gene CD86 and neoplasm.